Searched for
COMBIVIR
- Lupin’s numbers are below expectations: Ranjit Kapadia, Centrum BrokingIn an interview with ET Now, Ranjit Kapadia, Sr VP Institutional Research, Centrum Broking Pvt Ltd, gives his views on Lupin’s Q2 earnings....
- Preview: Lupin PAT seen up 4% YoY; higher input cost to dent marginsAccording to ET NOW, domestic formulations business is likely to grow by 20-23 per cent while the exports may see growth of 35 per cent. Hi...
- Launch of anti-HIV drug Combivir generic a positive development for LupinThe launch of Combivir generic is a positive development for Lupin. However, it will have to share the mkt with competitors viz. Teva & Aur...
- Lupin, Aurobindo get USFDA nod for HIV drugDrug firms Lupin Ltd and Aurobindo Pharma today said they have received approval to sell generic Combivir tablets, used in treating HIV inf...
- Hedged all forex exposure for short term: S Ramesh, CFO, LupinIn an interview with ET Now, S Ramesh, CFO, Lupin, talks about pharma and company's strategies.
- Glaxo takes new AIDS drug into final-stage testsGlaxoSmithKline and its partner Shionogi are progressing a new drug against HIV into final-stage clinical testing, ramping up competition i...
- It’s patent vs patient in AIDS fightThe battle lines between Western pharmaceutical transnationals and NGOs and patients’ associations are now drawn sharper than ever before. ...
- GSK withdraws patent application for AIDS drugGlobal pharmaceutical major GlaxoSmithKline (GSK) has withdrawn its patent application in India for anti-AIDS drug Combivir, which has been...
- Of patents and pre-grant oppositionsOn January 25 this year, the patent office in Chennai rejected a patent application by pharma MNC Novartis for its anti-cancer drug Glivec ...
Load More- Lupin, Aurobindo get USFDA nod for HIV drug
